Achieve Life Sciences 1 article

Achieve Life Sciences is a biopharmaceutical company characterized by smoking cessation therapeutics and cytisinicline nicotinic receptor partial agonist; its scientific profile also incorporates alpha4beta2 nicotinic acetylcholine receptor. Achieve Life Sciences combines alpha4beta2 nicotinic acetylcholine receptor, tobacco cessation pharmacotherapy and plant-derived cytisine analogue therapy, giving Achieve Life Sciences an explicit target or pathway context. The taxonomy keeps Achieve Life Sciences at the organization layer and treats nicotine receptor desensitization as supporting scientific context rather than an alternate entity name.

Biotechnology News & Analysis

October 15, 2026, 6:29 AM · 2 mins read

Lisata expands board as Phase 2b programs advance

Lisata appointed biopharma finance executive Jeffrey Farrow to a newly created board seat. He will join the Audit Committee as the company advances Phase 2b programs for severe hypertriglyceridemia and acromegaly.